SCHEMBL5458250

SCHEMBL5458250

CSc1nc(NC2CCCC2)n2nc(-c3ccccc3)cc2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.57
NPC1 O15118 7/20 0.57
LMNA P02545 2/20 0.57
KDM4E B2RXH2 5/20 0.43
HTT P42858 2/20 0.43
ADORA2A P29274 2/20 0.42
ADORA1 P30542 1/20 0.42
CALCA P06881 2/20 0.41
ADORA3 P0DMS8 1/20 0.41
MAPT P10636 3/20 0.40
CDC7 O00311 1/20 0.40
DBF4 Q9UBU7 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
ABCB1 P08183 1/20 0.40
NR2F2 P24468 1/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453634 0.77 KDM4E (0.44) RAB9ANPC1LMNAKDM4EHTT
SCHEMBL5451630 0.76 ADORA3 (0.41) RAB9ANPC1HTTADORA2AADORA1
SCHEMBL10628296 0.75 RAB9A (0.58) RAB9ANPC1LMNAKDM4EHTT
SCHEMBL10628212 0.74 NPC1 (0.57) RAB9ANPC1LMNAKDM4EHTT
SCHEMBL5449490 0.73 NPC1 (0.70) RAB9ANPC1LMNAKDM4EHTT
SCHEMBL5450469 0.71 RAB9A (0.40) RAB9ANPC1ADORA2AADORA1ADORA3
SCHEMBL10630094 0.71 NPC1 (0.67) RAB9ANPC1LMNAKDM4EHTT
SCHEMBL10634619 0.71 NPC1 (0.67) RAB9ANPC1LMNAKDM4EHTT
Hydrochloric Acid SCHEMBL11113246 0.71 KDM4E (0.49) RAB9ANPC1KDM4EHTTADORA2A
SCHEMBL14734373 0.70 PDE10A (0.53) RAB9ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232623-A1 Pyrazolopyrimidine and Pyrazolotriazine Derivatives and Pharmaceutical Compositions Containing Them GUDMUNDSSON KRISTJAN 2007-10-04 US disclosed
US-7247626-B2 Pyrazolopyrimidine derivatives and pharmaceutical compositions containing them SMITHKLINE BEECHAM CORPORATION (US) 2007-07-24 US disclosed
EP-1485385-B1 PYRAZOLOPYRIMIDINE AND PYRAZOLOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM CORP (US) 2005-08-17 EP disclosed
US-20050124616-A1 Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them SMITHKLINE BEECHAM CORPORATION 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124616-A1 Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them CYP3A5, CYP3A4, CYP3A7 RAB9A 3001/4885NPC1 801/4885LMNA 3910/4885
US-20070232623-A1 Pyrazolopyrimidine and Pyrazolotriazine Derivatives and Pharmaceutical Compositions Containing Them CYP3A5, CYP3A4, CYP3A7 RAB9A 3001/4885NPC1 801/4885LMNA 3910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.